CX Institutional Purchases 3,600 Shares of Eli Lilly and Company (NYSE:LLY)

CX Institutional lifted its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 15.2% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 27,223 shares of the company's stock after acquiring an additional 3,600 shares during the quarter. Eli Lilly and Company accounts for about 0.8% of CX Institutional's investment portfolio, making the stock its 27th largest holding. CX Institutional's holdings in Eli Lilly and Company were worth $22,484,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently made changes to their positions in the stock. GAMMA Investing LLC grew its position in Eli Lilly and Company by 103,831.6% during the first quarter. GAMMA Investing LLC now owns 14,866,380 shares of the company's stock valued at $12,278,292,000 after buying an additional 14,852,076 shares during the period. Norges Bank purchased a new position in shares of Eli Lilly and Company during the 4th quarter worth $8,407,908,000. Proficio Capital Partners LLC raised its holdings in Eli Lilly and Company by 100,387.1% in the 4th quarter. Proficio Capital Partners LLC now owns 5,202,215 shares of the company's stock worth $4,016,110,000 after purchasing an additional 5,197,038 shares during the period. Wellington Management Group LLP raised its holdings in Eli Lilly and Company by 19.0% in the 4th quarter. Wellington Management Group LLP now owns 12,625,925 shares of the company's stock worth $9,747,214,000 after purchasing an additional 2,012,129 shares during the period. Finally, Capital International Investors grew its holdings in Eli Lilly and Company by 23.2% during the fourth quarter. Capital International Investors now owns 8,730,758 shares of the company's stock valued at $6,740,272,000 after purchasing an additional 1,645,222 shares during the period. 82.53% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

LLY has been the subject of several analyst reports. Guggenheim reissued a "buy" rating on shares of Eli Lilly and Company in a report on Friday, May 23rd. The Goldman Sachs Group upgraded Eli Lilly and Company from a "neutral" rating to a "buy" rating and lowered their price objective for the company from $892.00 to $888.00 in a research report on Tuesday, April 8th. Wells Fargo & Company reissued an "overweight" rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. Cantor Fitzgerald started coverage on shares of Eli Lilly and Company in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $975.00 price objective on the stock. Finally, Erste Group Bank cut shares of Eli Lilly and Company from a "buy" rating to a "hold" rating in a research note on Thursday, June 5th. One research analyst has rated the stock with a sell rating, three have given a hold rating and eighteen have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $1,011.37.

Eli Lilly and Company Trading Up 0.9%

Shares of NYSE LLY traded up $7.67 during trading hours on Thursday, hitting $816.28. 896,779 shares of the company traded hands, compared to its average volume of 3,640,293. The stock has a market capitalization of $773.62 billion, a price-to-earnings ratio of 69.71, a price-to-earnings-growth ratio of 1.40 and a beta of 0.41. The company's 50 day moving average price is $771.74 and its 200 day moving average price is $800.91. Eli Lilly and Company has a 12 month low of $677.09 and a 12 month high of $972.53. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its earnings results on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.64 by ($1.30). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. The firm had revenue of $12.73 billion during the quarter, compared to the consensus estimate of $12.77 billion. During the same quarter last year, the business posted $2.58 EPS. Eli Lilly and Company's revenue was up 45.2% compared to the same quarter last year. On average, equities research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Friday, May 16th were given a dividend of $1.50 per share. The ex-dividend date was Friday, May 16th. This represents a $6.00 annualized dividend and a dividend yield of 0.74%. Eli Lilly and Company's dividend payout ratio (DPR) is 48.82%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.